SALT LAKE CITY — On this video, Jay Chhablani, MD, discusses findings introduced on the ARVO assembly from a section 2b examine evaluating suprachoroidal axitinib for neovascular age-related macular degeneration.
The trial enrolled 60 beforehand handled sufferers with steady imaginative and prescient and in contrast suprachoroidal axitinib (Clearside Biomedical) with intravitreal aflibercept 2 mg (Regeneron). Visible acuity and retinal thickness had been comparable between the 2 therapies, in keeping with Chhablani, professor of ophthalmology at College of Pittsburgh Faculty of Medication. Notably, 67% of sufferers within the axitinib arm remained injection-free for as much as 24 weeks, and no critical ocular unwanted effects had been noticed, he stated.
“The outcomes had been comparable, each by way of visible acuity in addition to central subfield retinal thickness,” Chhablani stated.
Reference:
- Wang R, et al. High line outcomes from ODYSSEY: A section 2b examine of suprachoroidally administered CLS-AX in individuals with neovascular age-related macular degeneration. Offered at: Affiliation for Analysis in Imaginative and prescient and Ophthalmology assembly; Could 4-8, 2025; Salt Lake Metropolis.
